Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Isis Pharmaceuticals, Inc. (NQ: ISIS)
20.46 USD  -0.20 (-0.97%)
Official Closing Price  /  Updated: 4:00 PM EDT, May 20, 2013  /  Add to My Watchlist      
View: Quote News Research
Stories about Isis Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Isis Pharmaceuticals Earnings In Retrospect: Down 5.6% in the Last 13 Days (ISIS)
Today 9:27 EDT
from Comtex SmarTrend® News Briefs
Aegerion’s Pricing Power Sends Shares Flying
May 17, 2013
Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) rocketed 33% higher in yesterday’s trading after the company reported that they would increase the price of flagship product Juxtapid (lomitapide) from... Read More
category AEGR , Bio/Wire
from Bio-Wire.Com
Bull’s Eye Report:Isis Pharmaceuticals (ISIS)
May 17, 2013
 Read More
category NASDAQ:ISIS , NYSEARCA:XBI
from InvestorPlace - Latest Headlines
StockCall Early Morning Insight into WCRX, DVAX, ISIS, ACT, and AVNR
May 15, 2013
from ACCESSWIRE
Snag ISIS Even Lower Than Its Secondary?
May 10, 2013
Looking back to 2 days ago, Isis Pharmaceuticals, Inc. (ISIS) priced a 9,000,000 share secondary stock offering at $19.00 per share. Read More
category Stocks
from Market News Video
Six Superstars for Your Biotech Portfolio: John McCamant
May 09, 2013
Six Superstars for Your Biotech Portfolio: John McCamant Source: Tracy Salcedo-Chourr? of The Life Sciences Report (5/9/13) http://www.thelifesciencesreport.com/pub/na/15256 We are in the “golden age,”... Read More
category AZN , JNJ , ALKS , and 8 more.
from Bio-Wire.Com
Isis Pharmaceuticals Earns $3.5M from Biogen Idec
May 09, 2013
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that is has earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase 2 study of... Read More
category Contracts , Benzinga , News , and 2 more.
from Latest Articles from Benzinga.com
Insights on Options Trading Activity for Isis Pharmaceuticals (ISIS)
May 09, 2013
NEW YORK (AVAFIN) -- During the last trading session, a new 90-day call record ... Read More
from AVAFIN
Isis Pharmaceuticals Prices 9M Share Offering at $19/Share
May 08, 2013
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of $19.00 per share. The... Read More
category Contracts , Management , Benzinga , and 4 more.
from Latest Articles from Benzinga.com
Upbeat Earnings Boost Markets To Another Record
May 08, 2013
Upbeat earnings boosted the markets further into record territory with the Dow gaining 48 points to 15,105. Nasdaq climbed 16 points to 3413. Read More
category Market News
from MarketMinute.com Market Updates
StreetInsider.com Pre-Open Movers 5/8: (ALXA) (LEDR) (WBMD) Higher; (FIO) (OCLR) (VCLK) Lower (more...)
May 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8316611 for the full story. Read More
from StreetInsider.com News Articles
Streetinsider.com After-Hours Movers 05/07: (WBMD) (WFM) (EA) Higher; (OCLR) (SYNC) (VCLK) Lower (more...)
May 07, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8314843 for the full story. Read More
from StreetInsider.com News Articles
Isis Pharmaceuticals (ISIS) to Offer 9M Shares
May 07, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8314835 for the full story. Read More
from StreetInsider.com News Articles
Isis Pharmaceuticals Announces Proposed Public 9M Share Offering of Common Stock
May 07, 2013
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that it intends to offer for sale 9 million shares of its common stock in an underwritten public offering. In connection with this offering, Isis... Read More
category Benzinga , Offerings , News , and 1 more.
from Latest Articles from Benzinga.com
Isis Pharmaceuticals, Inc. (ISIS) Reports In-Line Q1 Loss of 2c/Share
May 07, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8313395 for the full story. Read More
from StreetInsider.com News Articles
Isis Pharma (ISIS) Commences ISIS-STAT3Rx Phase 1b/2a in Advanced HCC
May 06, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8306205 for the full story. Read More
from StreetInsider.com News Articles
Isis Pharmaceuticals Initiates Clinical Study of ISIS-STAT3 Rx in Liver Cancer Patients
May 06, 2013
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC). HCC is a tumor... Read More
category Contracts , Management , Benzinga , and 3 more.
from Latest Articles from Benzinga.com
Wall Street Gets It Backward On Amgen Cholesterol Drug
April 29, 2013
Shares of Aegerion Pharmaceuticals have risen 200% since October on hopes that the company’s drug Juxtapid, a treatment for a rare genetic disease that causes super-high cholesterol and early heart... Read More
category NYSE:SNY , NASDAQ:REGN , NASDAQ:ISIS , and 2 more.
from Forbes Real Time
In Moribund Cholesterol Field, A New Drug Emerges
April 25, 2013
The artery disease that leads to heart attacks and strokes is the biggest killer in the United States. But when it comes to new drugs in development, atherosclerosis is dwarfed by cancer and... Read More
category NYSE:SNY , NYSE:PFE , NASDAQ:ISIS , and 2 more.
from Forbes Real Time
Best Stocks: Biotech Still Holding Top Spots
April 22, 2013
Biotech remains at the top of his week's "10.0 report" with three new buy ratings. Read More
category ONXX , ALNY , ARNA , and 1 more.
from Minyanville Headlines
Bio-Wire Weekly: April 15 – April 19 2013
April 22, 2013
Want this content delivered earlier & into your inbox? Sign up for our mailing list today! Bio-Wire Weekly: April 15 – April 19 2013 The Newsmakers: Vertex Pharmaceuticals (NASDAQ: VRTX) moved up... Read More
category THRX , SRPT , TTNP , and 6 more.
from Bio-Wire.Com
Highlights on Options Trading for Isis Pharmaceuticals
April 22, 2013
NEW YORK (AVAFIN) -- Unsual volume of put contracts traded on the exchange. Put's ... Read More
from AVAFIN
UPDATE: BMO Capital Markets Raises PT on Isis Pharmaceuticals Following Development Head Meeting
April 19, 2013
In a report published Friday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS ), and raised the price target from $22.00 to $31.00. In... Read More
category Benzinga , BMO Capital Markets , ISIS , and 3 more.
from Latest Articles from Benzinga.com
Isis Pharmaceuticals, Inc. Larger Than S&P 500 Component Advanced Micro Devices, Inc.
April 16, 2013
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Isis Pharmaceuticals, Inc. (ISIS) was identified as having a larger market cap than the smaller end of the... Read More
category Stocks
from Market News Video
Best Stocks: Four New Names, Four New Buys
April 15, 2013
Biotech names have leapt to the top of his week's "10.0 report" and offer 4 new buy ratings. Read More
category ALNY , ARNA , ISIS
from Minyanville Headlines
Uptrend Call Working As Isis Pharmaceuticals Stock Rises 93.5% (ISIS)
April 11, 2013
from Comtex SmarTrend® News Briefs
Roche to use Isis's technology to develop brain disorder drug
April 08, 2013
April 8 (Reuters) - Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the... Read More
category companyNews
from Reuters: Company News
Isis Pharma (ISIS) to resume trading at 9:45am ET
April 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8238276 for the full story. Read More
from StreetInsider.com News Articles
UPDATE: Roche, Isis Pharma Partner Against Hutington's Disease, Roche to Pay $30M Upfront
April 08, 2013
Roche and Isis Pharmaceuticals (NASDAQ: ISIS ) today announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO)... Read More
category Contracts , Benzinga , News , and 1 more.
from Latest Articles from Benzinga.com
Roche (RHHBY), Isis Pharma (ISIS) Enter Huntington's Disease Agreement; Value to Isis at $362M
April 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8238200 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here